Statins Are Associated With a Reduced Risk of Gastric Cancer: A Population-Based Case–Control Study

Chiu, Hui‐Fen; Ho, Shu Chen; Chang, Chih Ching; Wu, Trong Neng; Yang, Chun Yuh

doi:10.1038/ajg.2011.277

Cited by 77 publications

(87 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 The database has been employed to study beneficial and adverse effects of drug use. 22,23 The access to and use of the LHID for this study was approved by the National Health Research Institutes, which manages and constructs the database.…”

Section: Data Sourcementioning

confidence: 99%

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

Wang

Tsai

et al. 2013

The American Journal of Medicine

View full text Add to dashboard Cite

Section: Data Sourcementioning

confidence: 99%

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

Wang

Tsai

et al. 2013

The American Journal of Medicine

View full text Add to dashboard Cite

“…A previous case-control study using the Taiwan National Health Insurance Research Database showed that the adjusted OR was 0.49 (95% CI 0.30-0.79) among subgroups having been prescribed statins with cumulative defined daily doses ≥134.25, compared with no statin use [36]. A previous Korean study using a diabetic registry showed a 79% risk reduction of gastric cancer (adjusted OR 0.21; 95% CI 0.16-0.28) compared with 1:1 fashioned, age- and sex-matched controls [37].…”

Section: Statinsmentioning

confidence: 99%

Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors

Joo

Park

Chun

2017

Dig Dis

View full text Add to dashboard Cite

Background: Commonly used medications including statins, metformin, and proton pump inhibitors (PPIs) effectively reduce the risk of esophageal, gastric, and colorectal cancer (CRC). Summary: A number of observational studies and meta-analyses have shown that long-term statin use significantly reduces the incidence of gastrointestinal (GI) cancer. Moreover, statin use after GI cancer diagnosis has been significantly associated with better prognosis in large-scale cohort studies. Metformin was rigorously evaluated in a population-based study and meta-analysis, and was found to have an unexpected benefit in the prevention and prolonged survival of CRC patients with type 2 diabetes mellitus. In contrast, few studies have demonstrated the chemopreventive effect of metformin for esophageal and gastric cancer. Recent observational studies have demonstrated that PPIs effectively reduce the progression of nondysplastic Barrett's esophagus into esophageal adenocarcinoma in a dose-dependent manner. However, the association between chronic PPI use and CRC or gastric cancer risk is still controversial. It was expected that these 3 routinely used medicines would show a synergistic effect with conventional systemic chemotherapy in advanced GI cancers. However, recent phase III studies failed to show significantly better outcomes. Key Messages: Further studies are needed to identify “additional” anticancer effects of these commonly used medicines.

show abstract

“…Több tumorfajta esetén is szignifi káns negatív összefüggést írtak le a daganatok előfor-dulása és a statin szedése között. A legtöbb adat emész-tőszervi daganatok előfordulásának tanulmányozásából származott: főként a nyelőcső [32], a gyomor [33], a hasnyálmirigy [34] és a máj daganatait [35] vizsgálták, de az emlőrák prevenciójában is észleltek evidenciát [36].…”

Section: A Statinok Dokumentált Hatásai Randomizált Klinikai Tanulmánunclassified

Statins and gastrointestinal cancers

et al. 2014

View full text Add to dashboard Cite

A statinok tumorképződésre gyakorolt gátlóhatása állatkísérletekben és humán daganatsejtvonalakkal végzett vizsgá-latok során többféle emésztőrendszeri tumor esetében is igazolódott. A statinok kemopreventív hatásmechanizmusa még nem teljesen tisztázott, de a megnövekedett oxidatív stressz, a fokozott autofágia, a pro-és antiproliferatív fehérjék expressziójának megváltozása és a sejten belüli jelátviteli útvonalak befolyásolása szerepet játszik. A nagy esetszámú, randomizált klinikai tanulmányok egyelőre nem igazolták a kísérletes adatok alapján várt eredményeket. Jelen összefoglaló célja, hogy bemutassa a statinok kemopreventív szerepéről eddig megjelent irodalmi adatokat az egyes emésztőrendszeri daganatok vonatkozásában. A klinikai vizsgálatok eredményei alapján elmondható, hogy 10-20 mg/nap dózisú statin esetén nem vagy csak minimális tumorprotektív hatás észlelhető. Hidrofi l statinok esetén nincs, hidrofób statinoknál azonban szignifi káns a kemopreventív hatás. 30-40 mg/nap dózisban történő, hosszan tartó szedés hatásairól kevés adat áll rendelkezésre. A statinok hatásának hosszú távú vizsgálata -vegyülettípus és dózis szerint alcsoport-analízist végezve -valamennyi emésztőrendszeri daganat esetében szükséges a későbbiekben. A statinokkal történő kemoprevenció nem része a mindennapi orvosi gyakorlatnak. A statinok kemopreventív céllal történő alkalmazása nem helyettesítheti a rendszeres onkológiai szűrést és követést. Orv. Hetil., 2014, 155(18), 687-693. Kulcsszavak: statin, kemoprevenció, emésztőrendszeri daganatok Statins and gastrointestinal cancersThe antitumour effect of statins has already been proven in animal experiments and human cancer cell lines in several gastrointestinal cancers. The chemopreventive mechanism is not completely clarifi ed but the enhancement of oxidative stress, increased autophagy, altered expression of pro-and antiproliferative proteins and their infl uence on intracellular signaling pathways may play a role. Randomized studies, however, failed to confi rme the expected results obtained from experimental studies. The goal of this review is to summarize the data available in the literature regarding the chemopreventive effects of statins on several gastrointestinal cancers. Results of clinical trials suggest that 10-20 mg statin daily has no or minimal antitumour effect. Chemopreventive effect of hydrophilic statins could not be detected but it seems to be signifi cant in the case of hydrophobic statins. There are only few data available on the long-term daily use of 30-40 mg statins. Further long-term evaluation of the effect of statins regarding gastrointestinal cancers is needed, and an analysis of compound-and dose-related subgroups would be benefi cial. Chemoprevention with statins cannot yet be accepted as standard medical practice. Use of statins as chemopreventive agents cannot be a substitute for regular oncological screening or surveillance.

show abstract

Statins Are Associated With a Reduced Risk of Gastric Cancer: A Population-Based Case–Control Study

Abstract: The results of this study are the first to suggest that statins may reduce the risk of gastric cancer.

Cited by 77 publications

References 48 publications

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors

Statins and gastrointestinal cancers

Contact Info

Product

Resources

About